{
    "address": "Bertel Jungin aukio 1",
    "city": "Espoo",
    "country": "FI",
    "currency": "EUR",
    "cusip": "X3310Z105",
    "description": "Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson\u2019s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.",
    "employeeTotal": "",
    "exchange": "NASDAQ OMX HELSINKI LTD.",
    "finnhubIndustry": "Pharmaceuticals",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Pharmaceuticals",
    "gsector": "Health Care",
    "gsubind": "Pharmaceuticals",
    "ipo": "2014-06-11",
    "isin": "FI4000087861",
    "logo": "https://finnhub.io/api/logo?symbol=HRTIS.HE",
    "marketCapitalization": 25.56352,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Herantis Pharma Oyj",
    "phone": "35892221195.0",
    "sedol": "BMM1PL0",
    "shareOutstanding": 9.757068,
    "state": "ETELA-SUOMEN",
    "ticker": "HRTIS.HE",
    "weburl": "http://herantis.com"
}